NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda.

Patients on Adcetris and chemo had better progression-free and overall survival after six years of follow-up compared to those on chemo only.

It is estimated that about 800 people with Hodgkin lymphoma could benefit from the decision by the National Institute for Health and Care Excellence.

The National Institute for Health and Care Excellence (NICE) has recommended brentuximab vedotin combined with doxorubicin, ...

The UK’s health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended brentuximab ...

The study included patients who were heavily pre-treated, some of whom had received prior CAR-T therapy, and survival benefit was observed irrespective of CD30 expression. The ECHELON-3 study ...

Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended Adcetris ...

From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...